Why Biotech ETFs Are Surging as Treasury Yields Rise

Описание: Through September 28, 2026, XBI returned 28.56% and IBB returned 24.97% year to date, versus 13.15% for SPY, with dividends reinvested. Meanwhile, the nominal 10-year Treasury yield rose from 4.19% to 5.24%.

Why has biotech rallied despite that higher hurdle? We examine clinical progress, acquisitions, the IPO window, and where AI may help drug discovery. We also look at what could threaten the rally: failed trials, fewer deals, funding costs, and shareholder dilution. The ETF returns alone cannot tell us which factor drove the gains.

Created with the help from ChatGPT and Gemini Notebook. Not investment recommendations. For educational purposes only.

Hashtags
#Biotech #XBI #IBB #TreasuryYield #Investing